The study design: Prospective, randomised, multicentre trial recruiting from 31 Emergency Departments (EDs) of tertiary teaching hospitals with > 40,000 yearly ED visits, who adhere to surviving sepsis campaign guidelines, use serum lactate as a screen for cryptogenic septic shock but do not routinely use central venous oxygen saturation (ScvO 2 ) catheters or have a septic shock resuscitation bundle. Statistical analysis was conducted before unblinding.
The study patients: Inclusion criteria: Patients >18 years of age admitted to ED with a diagnosis of sepsis according to the physician with 52 systemic inflammatory response syndrome (SIRS) criteria and refractory hypotension (systolic <90) or lactate 54 despite 1000 ml fluid challenge in 30 min. All patients were enrolled within 2 h of detection of shock and within 12 h of admission.
Exclusion criteria: Patients with acute coronary syndrome, pulmonary oedema, status asthmaticus, major cardiac arrhythmia, gastrointestinal haemorrhage, seizures, drug overdose, burns, trauma, pregnancy, inter-hospital transfer, low CD4 count, and when treatment was considered futile.
Study groups: Each protocol was followed for 6 h post randomisation. Thereafter, care was left to the discretion of the responsible team. EGDT protocol group (439 patients): central venous saturation oximetry probe to target ScvO 2 of 70% with fluid boluses, haematocrit optimization to 0.3 or inotropic agents ( Figure 1 ). Standard protocol group (446 patients): peripheral access only, unless vasoactive agents were required or there was difficulty in obtaining intravenous access. Each protocol was followed for the first 6 h after randomisation ( Figure 2 ).
Both the protocol groups were cared for by the same trained and dedicated physician-led team. Adherence to study protocols was monitored by external study staff using a flow chart examining physiological goals and actions in attempt to achieve them. Usual care group (456 patients): This was left to the discretion of a non-study clinician.
Results-see tables overleaf.
EBM Questions
1. Do the methods allow accurate testing of the hypothesis? Yes. This was a multi-centre, randomized, comparison of protocols against a nonstandardised approach. The same team provided care to the patients randomised to the protocolised care arms, but a separate non-study team provided care to the usual care group in order to minimise any operator bias. Study physicians could not be blinded, but data analysis was performed by blinded study personnel. Adherence to protocols was monitored by study staff using an adherence flowchart for each protocol arm. 2. Do the statistical tests correctly test the results to allow differentiation of statistically significant results? Yes. Data were analysed on an intention-to-treat principle. The investigators tested sequentially whether protocol-based resuscitation (EGDT or standard-based therapy) was superior to usual care, and then whether protocol-based EGDT was superior to protocol-based standard therapy. Power calculation based upon 80% to detect a mortality reduction of 6-7% gave a sample size of 1950 patients. This assumed a mortality of 30-46% in the usual care group based on the similar study by Rivers et al. 1 However, analysis before 1300 patients showed a lower than expected mortality of 20% which was also consistent with another study. 2 Recalculation gave a Health Evaluation (APACHE) II score, baseline serum lactate levels and time from shock detection to randomization was also performed using logistical regression to test for correlation.
Are the conclusions valid in light of the results?
Yes. Baseline characteristics between the groups were not significantly different in terms of demographics, source of sepsis, APACHE II score, serum lactate, or time to randomization. Adherence to protocols was high, with only 11.9% and 4.4% patients being non-adherent in the EGDT and standard-therapy groups, respectively. Treatment in terms of intravenous fluid volume, vasoactive drug usage and blood transfusion was not significantly different in the 6-72 h period. Use of antibiotics, glucocorticoids, and activated protein C was also not significant between the groups. However, it is worth noting that at 6 h the average pH values in the protocolbased groups were significantly lower than the usual care group at 7.1 and 7.4, respectively (Table 4 ). This could imply increased severity of sepsis in those groups. This theory might be supported by the fact that significantly more patients in the EGDT group were admitted to an intensive care unit (Table 1 ). 4. Did results get omitted and why? Yes. Ten patients withdrew their consent from the study, leaving 1341 patients in the analysis. 5. Did the author suggest any further areas for research? No. However, the authors do comment on the study's inability to examine what aspects of the very early stages of a patient's care may have on outcomes in sepsis. 6. Did they make recommendations based on the results and were they appropriate? No. No specific recommendations were made, but the authors declared that if patients with sepsis are identified early and received antibiotics in addition to other non-resuscitative aspects of care promptly, then there was no advantage in using a protocol-based resuscitation using central venous monitoring. 7. Is the study relevant to my clinical practice? Yes.
The patients in the study are fully representative of UK patients with septic shock. EGDT using ScvO 2 has been part of fluid resuscitation in sepsis along with other patient cohorts for over 10 years, based on papers such as the Rivers study, 1 and Shoemaker. 3 The surviving sepsis campaign guidelines recommended use of ScvO 2 , and thus it is considered best practice. This paper calls in to question the positive impact this has on patient outcome. 8. What level of evidence does the study represent?
1B. The study design and testing of adherence to study protocol, together with correct and interim power analysis make this a good quality study. 9. What grade of recommendation can I make on this result alone? A 10. What grade of recommendation can I make when this study is considered along with other available evidence? A. The recent ARISE trial 4 of similar design and quality yielded similar findings. The early study by Rivers et al. 1 had a higher mortality rate, was single-centred and had other possible confounding issues. The ProMISe trial, 5 a third trial of this nature will supply further evidence on the use of EGDT for sepsis. 11. Should I change my practice because of these results? No. Both ProCESS, and ARISE showed overall mortality rates to be substantially lower than in the original Rivers study. This is possibly due to the surviving sepsis campaign generating increased awareness, diagnosis and early treatment of septic shock with appropriate antibiotics and fluid resuscitation. This would suggest that the 'early' part of EGDT is the important component, and that current day standard 'accepted care' of sepsis gave no worse outcome than goal-directed therapy. The surviving sepsis campaign intends to issue a statement based on the results of the three trials after they are published. 12. Should I audit my practice because of these results? Possibly. Central venous catheters (CVC) are associated with a degree of morbidity and therefore their use must be justified. Sole use of CVCs for monitoring ScvO 2 could therefore be considered unnecessary and not best practice.
